Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.43 |
| ▸ | CA12 | O43570 | 5/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.37 |
| ▸ | CA7 | P43166 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MME | P08473 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | ESRRB | O95718 | 1/20 | 0.31 |
| ▸ | PTPRB | P23467 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4904213 | 1.00 | CA14 (0.43) | CA14CA12CA9CA7SMN1; SMN2 | |
| SCHEMBL19963061 | 0.84 | CA14 (0.40) | CA14CA12CA9CA7SMN1; SMN2 | |
| SCHEMBL4372500 | 0.80 | CA14 (0.45) | CA14CA12CA9CA7SMN1; SMN2 | |
| SCHEMBL27949562 | 0.79 | CA14 (0.41) | CA14CA12CA9CA7SMN1; SMN2 | |
| SCHEMBL4372490 | 0.78 | CA14 (0.43) | CA14CA12CA9CA7SMN1; SMN2 | |
| SCHEMBL31247919 | 0.78 | CA14 (0.43) | CA14CA12CA9CA7SMN1; SMN2 | |
| SCHEMBL7337250 | 0.75 | GABRR1 (0.41) | — | |
| SCHEMBL7337243 | 0.75 | GABRR1 (0.41) | — | |
| SCHEMBL16018886 | 0.72 | GAA (0.41) | CA14CA12CA9CA7SMN1; SMN2 | |
| SCHEMBL2566028 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688741-A1 | COMPOUNDS FOR TREATING FIBROTIC DISEASES | Meta-Immune, Inc. (KR) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024249867-A1 | COMPOUNDS FOR TREATING FIBROTIC DISEASES | AM SCIENCES (KR) | 2024-12-05 | — | — | WO | disclosed |
| EP-3227262-B1 | SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS INC (US) | 2020-05-13 | — | — | EP | disclosed |
| US-10428041-B2 | Pyridyl reverse sulfonamides for HBV treatment | NOVIRA THERAPEUTICS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190152940-A1 | Pyridyl Reverse Sulfonamides For HBV Treatment | NOVIRA THERAPEUTICS, INC. | 2019-05-23 | — | — | US | disclosed |
| US-10160742-B2 | Pyridyl reverse sulfonamides for HBV treatment | NOVIRA THERAPEUTICS, INC. (US) | 2018-12-25 | — | — | US | disclosed |
| US-20180051000-A1 | Pyridyl Reverse Sulfonamides For HBV Treatment | NOVIRA THERAPEUTICS, INC. | 2018-02-22 | — | — | US | disclosed |
| CN-107406378-A | Sulfurized alkyl compounds and pyridine trans sulfonamide compounds for HBV treatment | 诺维拉治疗公司 | 2017-11-28 | — | — | CN | disclosed |
| EP-3227262-A1 | SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT | Novira Therapeutics Inc. (US) | 2017-10-11 | — | — | EP | disclosed |
| US-9765050-B2 | Pyridyl reverse sulfonamides for HBV treatment | NOVIRA THERAPEUTICS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| EP-0804428-B1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | SEARLE LLC (US) | 2007-12-26 | — | — | EP | disclosed |
| US-7297793-B2 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | G.D. SEARLE, LLC (US) | 2007-11-20 | — | — | US | disclosed |
| US-20060199822-A1 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-09-07 | — | — | US | disclosed |
| US-7091219-B2 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1586558-A2 | Bis-sulfonamide hydroxyethylamino retroviral protease inhinitors | G.D. Searle LLC. (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040063771-A1 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2004-04-01 | — | — | US | disclosed |
| US-6569882-B2 | Viricides; enzyme inhibitors | G. D. SEARLE & CO. | 2003-05-27 | — | — | US | disclosed |
| US-20030013751-A1 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2003-01-16 | — | — | US | disclosed |
| US-6384036-B1 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | G.D. SEARLE & CO. | 2002-05-07 | — | — | US | disclosed |
| WO-1996022287-A1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152940-A1 | Pyridyl Reverse Sulfonamides For HBV Treatment | HAVCR2, HCCS, NR1H4 | CA14 2933/4885CA12 3206/4885CA9 3721/4885 |
| US-10428041-B2 | Pyridyl reverse sulfonamides for HBV treatment | HAVCR2, HCCS, NR1H4 | CA14 2933/4885CA12 3206/4885CA9 3721/4885 |
| US-20180051000-A1 | Pyridyl Reverse Sulfonamides For HBV Treatment | HAVCR2, HCCS, NR1H4 | CA14 2933/4885CA12 3206/4885CA9 3721/4885 |
| US-20030013751-A1 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | DNPEP, PRSS1, PREP | CA14 948/4885CA12 1735/4885CA9 769/4885 |
| US-10160742-B2 | Pyridyl reverse sulfonamides for HBV treatment | HAVCR2, HCCS, NR1H4 | CA14 2933/4885CA12 3206/4885CA9 3721/4885 |
| US-20060199822-A1 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | PRSS1, DNPEP, PREP | CA14 959/4885CA12 1733/4885CA9 776/4885 |
| US-20040063771-A1 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | DNPEP, PRSS1, PREP | CA14 948/4885CA12 1735/4885CA9 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.